Dr. Burton is also company Founder. To maintain the company's basic-research pipeline he also retains as Adjunct Associate Professor his former faculty and principal investigator status at the University of Minnesota-Twin Cities' Department of Pharmacology, National Cancer Institute-Comprehensive Cancer Center, and Minnesota Supercomputing Institute.
Dr. Burton's commercial biotechnology contributions include two biotech patents (U.S. Patents 5,223,610 and 5,416,017) for cellular-level "physiological engineering," and one patent pending for an anti-inflammatory wound-healing accelerant. He was also an early consultant on cDNA-fingerprinting (genome expression-profiling) technology for the founders of two other biotechnology and bioinformatics companies, Digital Gene Technologies, Inc., and Neurome, Inc., of La Jolla. He has authored 33 academic research articles and obtained 22 research grants for discoveries or methods in molecular genetics, genomics and genome expression analysis, biotechnology, genetic and physiological engineering, endocrinology, cancer genetics and biology, neurobiology and behavior, pharmacology, neuropharmacology and neuroimmunopharmacology.
Methods or products Dr. Burton has created include polymerase timepoint subcloning, DNA sandwich hybridization, antiviral polyribozymes, intracellular second-messenger stimulating transgenes, physiological engineering, behavioral circuit-testing, Big Mice, Ticcy Mice, and behavioral waveform display. His past scientific discoveries include the Mammalian LINES-1 retroposon, cAMP carcinogenesis, Ets Homologous Factor (EHF) tumor suppressor, "cluster-bomb" carcinogenesis, and the Cortical-limbic Glutamatergic Neuron (CGN) model of tics and compulsions (which inspired clinical validation of new drugs to ameliorate these disorders).
Dr. Burton also has scientifically advised 88 students, technicians or postdocs, has directed the University's Medical School Pharmacology courses, and is a top-ranked UMN lecturer. He has served as grant reviewer for the U.S. National Science Foundation (NSF), the University of Leuven Research Council and the Israel Research Foundation, as manuscript reviewer for 17 scientific journals, and in five professional societies and consortia (FASEB, ASPET, SFN, AAAS, MNCAS).
Dr. Wei, a co-inventor with Dr. Burton of one patent pending for an anti-inflammatory wound-healing accelerant, is a Distinguished McKnight University Professor in the UMN Medical School's Department of Pharmacology. As a Principal Investigator at the "U" and recipient of multiple NIH research grants, Dr Wei has authored 159 research papers on retinoid regulation and the role of multiple intracellular signaling molecules in neural function, osteoporosis, insulin-resistance, obesity, diabetes, atherosclerosis, inflammation, and wound-healing.
Dr. Yi-Wei (Vincent) Lin, a co-inventor with Drs. Burton & Wei of one patent pending for an anti-inflammatory wound-healing accelerant, is also a Postdoctoral Associate of Dr. Wei in the University of Minnesota Medical School's Department of Pharmacology, and has authored 18 research papers on the role of retinoid and other signaling molecules' regulation of macrophage function, inflammation, insulin-resistance, and wound-healing.
Harlan Jacobs is the former CFO of FilmTec Corp. of Columbia Heights, MN; and is President of Genesis Business Centers, Ltd.
Copyright © 2019, Psyncretis, Inc. All rights reserved.